Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study

A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK

Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study

Non-price-related determinants of value and access for novel non-small cell lung cancer treatments: a cross-country review of HTA decision making

Economic evaluation of single versus combination immuno-oncology therapies: application of a novel modelling approach in metastatic melanoma

Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective

Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation

Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma

Modeling the economics outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes